Follicular Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week (New A2) mosunetuzumab Sensitive : A1 NCCN - 1wk	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week mosunetuzumab Sensitive : A1 NCCN - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week (New A2) tazemetostat Sensitive : A2 NCCN - 1wk	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week tazemetostat Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
EZH2 wild-type	Follicular Lymphoma	EZH2 wild-type	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + obinutuzumab Sensitive: A2 - Guideline rituximab + obinutuzumab Sensitive : A2	rituximab + obinutuzumab Sensitive: A2 - Guideline rituximab + obinutuzumab Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2	G-CHOP Sensitive: A2 - Guideline G-CHOP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	GVD Sensitive: A2 - Guideline GVD Sensitive : A2	GVD Sensitive: A2 - Guideline GVD Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	DHAX Sensitive: A2 - Guideline DHAX Sensitive : A2	DHAX Sensitive: A2 - Guideline DHAX Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2

Follicular Lymphoma

Associations(79)

Associations
(79)